The nasal testosterone spray, Natesto, was approved even as the U.S. Food & Drug Administration (FDA) investigated a possible link between the use of low-T therapy and certain cardiovascular side effects. Since its launch on the market, the FDA has ordered the manufacturers of all prescription testosterone treatments to add new warnings to their labels regarding a potential association with an increased risk of heart attack and stroke.
The nationwide law firm of Bernstein Liebhard LLP is now offering free, no-obligation legal reviews to men who may have suffered a heart attack, stroke, deep vein thrombosis, or pulmonary embolism while using prescription low-T therapy. If you are interested in filing a Natesto lawsuit, please contact our legal staff by calling (888) 994-5118.
The FDA approved sale of Natesto in May 2014 to treat adult men who have low or no testosterone due to certain underlying medical conditions. The safety and efficacy of Natesto and other prescription low-T drugs in treating men who are experiencing diminished testosterone levels due to aging has not been proven.
The recommended dose of Natesto is 11 mg administered intranasally three times daily for a total daily dose of 33 mg. Natesto should be administered once in the morning, once in the afternoon and once in the evening (6 to 8 hours apart), preferably at the same time each day.
Side effects that may accompany the use of Natesto include:
The FDA announced its testosterone safety review after several studies raised questions about the cardiovascular side effects associated with low-T therapy:
If you or a man you care about suffered a heart attack, stroke or dangerous blood clot while using Natesto, now is the time to ensure your legal rights are protected. To learn more about the growing testosterone litigation, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.